What's in Yih-Ing Hser's pipeline?

Yih-Ing Hser has 1 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Yih-Ing Hser's portfolio?

Top competitors by shared drug class: Brigham and Women's Hospital, Orexo AB, Orient Pharma Co., Ltd., Rutgers, The State University of New Jersey.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/yih-ing-hser.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Yih-Ing Hser — Portfolio Competitive Intelligence Brief

Yih-Ing Hser pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Sublingual buprenorphine-naloxone	Sublingual buprenorphine-naloxone	phase 3	Opioid partial agonist	Opioid receptors	Pain

Therapeutic area mix

Pain · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Brigham and Women's Hospital · 1 shared drug class
Orexo AB · 1 shared drug class
Orient Pharma Co., Ltd. · 1 shared drug class
Rutgers, The State University of New Jersey · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Yih-Ing Hser:

Cite this brief

Drug Landscape (2026). Yih-Ing Hser — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/yih-ing-hser. Accessed 2026-05-16.